第 1 到 14 筆結果,共 14 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2020 | Landscape of mitochondria genome and clinical outcomes in stage 1 lung adenocarcinoma | Raghav L.; Chang Y.-H.; Hsu Y.-C.; Li Y.-C.; Chen C.-Y.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Chuang C.-Y.; Lee M.-H.; Wang C.-L.; HUEI-WEN CHEN ; SUNG-LIANG YU ; SHENG-FANG SU ; Yuan S.-S.; Chen J.J.W.; Ho S.-Y.; Li K.-C.; PAN-CHYR YANG ; Chang G.-C.; Chen H.-Y. | Cancers | 8 | 8 | |
2 | 2019 | The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan | Tseng C.-H.; Tsuang B.-J.; CHUN-JU CHIANG ; Ku K.-C.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; SUNG-LIANG YU ; WEN-CHUNG LEE ; Liu T.-W.; CHANG-CHUAN CHAN ; Chang G.-C. | Journal of Thoracic Oncology | 115 | 106 | |
3 | 2019 | High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients | Hsu K.-H.; Huang Y.-H.; Tseng J.-S.; Chen K.-C.; Ku W.-H.; KANG-YI SU ; Chen J.J.W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang T.-Y.; Chang G.-C. | Lung Cancer | 64 | 52 | |
4 | 2018 | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | Tseng J.-S.; Yang T.-Y.; Wu C.-Y.; Ku W.-H.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Journal of Immunotherapy | 29 | 25 | |
5 | 2018 | Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma | KANG-YI SU ; Tseng J.-S.; Liao K.-M.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; PAN-CHYR YANG ; SUNG-LIANG YU ; Chang G.-C. | PLoS ONE | 18 | 13 | |
6 | 2018 | Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib treatment | Tseng J.-S.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Cancer Research and Treatment | 5 | 5 | |
7 | 2016 | Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients | Huang Y.-H.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; KANG-YI SU ; Chen H.-Y.; Chang C.-S.; Chen J.J.W.; SUNG-LIANG YU ; HUEI-WEN CHEN ; Yang T.-Y.; Chang G.-C. | Journal of Thoracic Disease | 2 | 2 | |
8 | 2016 | Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients | Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; SUNG-LIANG YU ; KANG-YI SU ; CHONG-JEN YU ; CHAO-CHI HO ; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; PAN-CHYR YANG ; Chen J.J.W.; Chang G.-C. | Oncotarget | 9 | 9 | |
9 | 2016 | EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma | Chen H.-Y.; Liu C.-H.; Chang Y.-H.; SUNG-LIANG YU ; Ho B.C.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Chang C.-S.; Li Y.-C.; Li K.-C.; Chang G.-C.; PAN-CHYR YANG | Oncotarget | 14 | 16 | |
10 | 2016 | The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M | Tseng J.-S.; KANG-YI SU ; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen H.-Y.; Tsai C.-R.; SUNG-LIANG YU ; Chang G.-C. | Oncotarget | 24 | 23 | |
11 | 2015 | Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan | Hsu K.-H.; CHAO-CHI HO ; Hsia T.-C.; Tseng J.-S.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Chang G.-C. | PLoS ONE | 98 | 92 | |
12 | 2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 13 | 12 | |
13 | 2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
14 | 2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 28 | 26 |